Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 316: H2 Influenza HA Ferritin Vaccine Phase I
NCT03186781Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRC-FLUNPF081-00-VP in influenza (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration, Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of DNA A/Sing Product Administration and 6 more. Started Oct 2017; status: completed.
02
Drugs
VRC-FLUNPF081-00-VP
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03186781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186781.